Terumo's customer, Europlasma has become the first blood centre in Austria to receive authorisation from AGES, the Austrian Agency for Health and Food Safety, to use the Mirasol pathogen reduction technology system with platelets. The authorisation enables the blood centre to adopt an enhanced approach to blood safety, using the Mirasol system for all platelets collected for transfusion.
Terumo's Trima Accel automated blood collection system, Europlasma produces double- and triple-unit platelet concentrates (PCs) that can be pathogen-reduced with a single Mirasol treatment. The Mirasol system reportedly offers Europlasma key benefits not offered by other pathogen reduction technologies, including the use of riboflavin (vitamin B2), a naturally-occurring, non-toxic compound that enables safe handling conditions for blood centre personnel, cost effectiveness, with treatment of double and triple-dose PCs collected on Terumo's Trima Accel system; and efficient, flexible and simple processes with minimal loss of product, immediate availability of products for delivery to patients, and easy integration into blood centre operations.
The Mirasol system currently is used in more than 50 blood centres in 15 countries throughout Europe, the Middle East and Africa. Key drivers toward pathogen reduction technology include: enhanced safety - with emphasis on increased protection against bacteria and emerging infectious threats; and the ability to replace existing safety interventions, such as bacterial detection, gamma irradiation and CMV screening.